CICipla500087Pharmaceuticals

Cipla reported modest Q2 numbers but maintained its US revenue and EBITDA margin guidance, prompting mixed brokerage reactions

By ScoutQuest · Wed 28 Oct 2026, 8:58 AM IST · 1 min read

US revenue guidance

1 billion dollars

EBITDA margin guidance

18 to 20 percent

Q4 US sales estimate (Kotak)

233 million dollars

Heard on business television between 09:02:28 - 09:05:28 IST.

• Cipla reported a modest set of Q2 numbers but maintained guidance of $1 billion in US revenue and 18-20% EBITDA margin.
• Jefferies upgraded the stock to hold and hiked its target price, saying Q2 was 'a mess' but valuations limit downside, with biosimilars offering future growth optionality.
• Kotak maintained buy, saying lower R&D drove EBITDA beats and steady progress in US sales, factoring in $233 million of US sales in Q4.
• Citi maintained buy, saying margin improvement should sustain decent performance across segments but cut EPS estimates on lower US sales and higher tax rate.
• UBS maintained neutral, saying Q2 was modest, US execution is key for H2, and India business remains robust with better medium-term growth visibility.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.

About ScoutQuest · Logos provided by Logo.dev